½ÃÀ庸°í¼­
»óǰÄÚµå
1463090

¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : ¹æ¹ýº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2032³â)

Viral Clearance Market Share, Size, Trends, Industry Analysis Report, By Method (Viral Removal Method, Viral Inactivation Method, and Viral Detection Method); By Application; By End User; By Region; Segment Forecast, 2024 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ¼¼°èÀÇ ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 14¾ï 6,476¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ¼³¹®Á¶»ç º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇÐÀ» ÀÚ¼¼È÷ ÆÄ¾ÇÇϰí ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

¹ÙÀÌ¿À½Ã¹Ð·¯¿Í Á¦³×¸¯ ÀǾàǰ¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä Áõ°¡¿Í ¸¸¼º Áúȯ¿¡ ´ëÇÑ °íµµ·Î Àú·ÅÇÑ Ä¡·á¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÇöÀúÇÑ ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ °³¹ß Ãʱ⠴ܰ迡¼­ ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ¹× ºÒȰ¼ºÈ­ °ËÃâÀÇ º¸±ÞÀÌ ±Þ¼ÓÈ÷ ÁøÇàµÇ°í ÀÖÀ¸¸ç, ´ë±â¾÷ Á¦¾à ±â¾÷°ú »ý¸í °øÇÐ ±â¾÷ »çÀÌ¿¡¼­ ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ¾Æ¿ô¼Ò½Ì¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö°í ÀÖ´Â °Íµµ ¼¼°è ½ÃÀå ¼ºÀåÀ» ´õ¿í ¹Ð¾î¿Ã¸± °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¹¸¦ µé¾î, 2023³â 6¿ù, TexcellÀº ºÏ¹Ì¿¡ ÃֽнÃÇè ½Ã¼³À» °³¼³ÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ´Â ¹ÙÀÌ¿À Ä¡·áÁ¦ ¹× ÀÇ·á±â±âÀÇ ¹ÙÀÌ·¯½º ¾ÈÀü¼º Çâ»óÀ» À§ÇÑ È¸»çÀÇ ³ë·ÂÀ» º¸¿©ÁÝ´Ï´Ù. ÀÌ »õ·Î¿î ½Ã¼³Àº ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º¿Í ¹ÙÀÌ¿À ¼¼ÀÌÇÁƼÀÇ µ¿½Ã Å×½ºÆ®¸¦ Áö¿øÇϵµ·Ï Ưº°È÷ ¼³°èµÇ¾ú½À´Ï´Ù.

»ý¹° Á¦Á¦¿¡¼­ À¯ÇØÇÑ ¹ÙÀÌ·¯½º¸¦ °Ë»çÇÏ´Â µ¥´Â ¿©·¯ °¡Áö ¹æ¹ýÀÌ »ç¿ëµË´Ï´Ù. ¾Ë·ÁÁø ¹× ¾Ë·ÁÁöÁö ¾ÊÀº ¿À¿° ¹ÙÀÌ·¯½º¸¦ Á¤È®ÇÏ°í ½Å¼ÓÇÏ°Ô °ËÃâÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â Â÷¼¼´ë ½ÃÄö¼­ÀÇ ÃâÇöÀ¸·Î ±× ¼ö°¡ Á¡Á¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Â÷¼¼´ë ½ÃÄö¼­´Â ±¤¹üÀ§ÇÑ ¹ÙÀÌ·¯½º ¿À¿°¹°ÁúÀÇ ¹Î°¨ÇÏ°í Æ¯ÀÌÇÑ °Ë»ç¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© ½ÃÀå ¼ºÀå ÀáÀç·ÂÀ» âÃâÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 7¿ù, Integrated DNA Technologies´Â 'xGen Respiratory Virus Amplicon Panel'À̶ó´Â »õ·Î¿î Â÷¼¼´ë ½ÃÄö½Ì ¼Ö·ç¼ÇÀ» ¹ßÇ¥Çß½À´Ï´Ù.

¶ÇÇÑ, Àΰ£ ¸é¿ª°áÇÌ ¹ÙÀÌ·¯½º, °£¿°, µðÄ«¹ÙÀÌ·¯½º µî ¿©·¯ À¯ÇüÀÇ ¹ÙÀÌ·¯½º¼º Áúȯ¿¡ ÀÇÇØ ¹ÙÀÌ·¯½ºÀÇ ¾ÈÀü¼º°ú ÇコÄÉ¾î »ê¾÷¿¡¼­ÀÇ ±× Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ À¯ÀüÀÚ Ä¡·á¿Í ¸ÂÃãÇü ÀÇ·áÀÇ Çʿ伺¿¡ ÀÇÇØ Ç¥ÀûÀ» Á¼Èù Ç×¹ÙÀÌ·¯½º Ä¡·á³ª ¸é¿ª ¹ÝÀÀÀÇ °­È­°¡ °¡´ÉÇØÁ® ³ª¾Æ°¡ ½ÃÀå¿¡ Å« ¼ºÀåÀÇ °¡´É¼ºÀ» âÃâÇϰí ÀÖ½À´Ï´Ù.

¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ¹ý ºÐ¾ß´Â À¯ÀÍÇÑ Æ¯¼º°ú ¼¼°èÀÇ ½ÅÇü ¹ÙÀÌ·¯½º À§ÇùÀÇ »ó½ÂÀ¸·Î ÁÖ¸ñÇÒ¸¸ ÇÑ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¹é½Å ºÎ¼­°¡ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇßÀ¸³ª, ÀÌ´Â ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä¿Í ¿ä±¸»çÇ×ÀÌ Áõ°¡ÇÏ¿© ȯÀÚÀÇ ¿¹¹æÁ¢Á¾À» ÃËÁøÇϱâ À§ÇÑ ´Ù¾çÇÑ À¯ÇüÀÇ ¹é½Å¿¡ ÀÖ½À´Ï´Ù.

CRO ºÐ¾ß´Â Ãʱ⠴ܰèÀÇ °³¹ß°ú ½ÃÇè ¼­ºñ½º ¾Æ¿ô¼Ò½ÌÀÇ º¸±ÞÀ¸·Î ÀÎÇØ »ó´çÇÑ ¼ºÀå·üÀ» º¸ÀÔ´Ï´Ù.

°Å´ëÇÑ ¹Ì°³Ã´ ½ÃÀåÀÇ Á¸Àç¿Í °¡Ã³ºÐ ¼Òµæ Áõ°¡·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì´Â ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½ºÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô±â ¶§¹®¿¡ ¼¼°è ½ÃÀåÀ» ¼®±ÇÇϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå ±â¾÷Àº Charles River Laboratories, Merck KgaA, Syngene International Limited, WuXi Biologics, Clean Cells, Allure Medical Group µîÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå ÀλçÀÌÆ®

  • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-ÃÖÁ¾ »ç¿ëÀÚ ½º³À¼¦
  • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ ¹× ±âȸ
      • »ý¹° Á¦Á¦ ¹× ¹é½Å ¼ö¿ä Áõ°¡¿Í ¿¬±¸ °³¹ßºñ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù.
      • ¹ÙÀÌ·¯½º °¨¿° Áõ°¡
    • ¾ïÁ¦¿äÀÎ ¹× °úÁ¦
      • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ±â¼úÀÇ º¹À⼺
  • PESTEL ºÐ¼®
  • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀåÀÇ ÃÖÁ¾ »ç¿ëÀÚ µ¿Çâ
  • ¹ë·ùüÀÎ ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®

Á¦5Àå ¼¼°èÀÇ ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ¹æ¹ýº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­¹®
  • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ¹æ¹ý
  • ¹ÙÀÌ·¯½º ºÒȰȭ¹ý
  • ¹ÙÀÌ·¯½º °ËÃâ ¹æ¹ý

Á¦6Àå ¼¼°èÀÇ ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ¿ëµµº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­¹®
  • Ç÷¾× ¹× Ç÷¾× Á¦Á¦
  • ÀçÁ¶ÇÕ ´Ü¹éÁú
  • ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á Á¦Ç°
  • ¹é½Å
  • ±âŸ

Á¦7Àå ¼¼°è ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­¹®
  • Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ¾÷°è
  • Çмú¿¬±¸±â°ü
  • CRO
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­¹®
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀåÀÇ Æò°¡ : Áö¿ªº°(2019-2032³â)
  • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-ºÏ¹Ì
    • ºÏ¹Ì : ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ¹æ¹ýº°(2019-2032³â)
    • ºÏ¹Ì : ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2019-2032³â)
    • ºÏ¹Ì : ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ¿ëµµº°(2019-2032³â)
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-¹Ì±¹
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-ij³ª´Ù
  • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-À¯·´
    • À¯·´ : ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ¹æ¹ýº°(2019-2032³â)
    • À¯·´ : ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2019-2032³â)
    • À¯·´ : ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ¿ëµµº°(2019-2032³â)
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-¿µ±¹
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-ÇÁ¶û½º
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-µ¶ÀÏ
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-ÀÌÅ»¸®¾Æ
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-½ºÆäÀÎ
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-³×´ú¶õµå
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-·¯½Ã¾Æ
  • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ¹æ¹ýº°(2019-2032³â)
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2019-2032³â)
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ¿ëµµº°(2019-2032³â)
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-Áß±¹
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-Àεµ
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-¸»·¹À̽þÆ
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-ÀϺ»
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-Àεµ³×½Ã¾Æ
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-Çѱ¹
  • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ¹æ¹ýº°(2019-2032³â)
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2019-2032³â)
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ¿ëµµº°(2019-2032³â)
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-»ç¿ìµð¾Æ¶óºñ¾Æ
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-UAE
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-À̽º¶ó¿¤
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-³²¾ÆÇÁ¸®Ä«
  • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ¹æ¹ýº°(2019-2032³â)
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2019-2032³â)
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå : ¿ëµµº°(2019-2032³â)
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-¸ß½ÃÄÚ
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-ºê¶óÁú
    • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå-¾Æ¸£ÇîÆ¼³ª

Á¦9Àå °æÀï ±¸µµ

  • È®´ë ¹× Àμö ºÐ¼®
    • È®´ë
    • Àμö
  • ÆÄÆ®³Ê½Ê, Çù¾÷, °è¾à ¹× Àü½Ãȸ

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Allure Medical Group
  • Charles River Laboratories
  • Clean Cells
  • Creative Biogene
  • Eurofins Scientific SE
  • Kedrion
  • Labor Dr. Merk & Kollegen GmbH
  • Merck KGaA
  • Microbiologics
  • Sartorius AG
  • Syngene International Limited
  • Texcell
  • ViruSure GmbH
  • Wuxi Biologics
AJY 24.04.25

The global viral clearance market size is expected to reach USD 1464.76 million by 2032, according to a new study by Polaris Market Research. The report "Viral Clearance Market Share, Size, Trends, Industry Analysis Report, By Method (Viral Removal Method, Viral Inactivation Method, and Viral Detection Method); By Application; By End User; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing demand for biosimilars and generics worldwide and greater need for sophisticated and cheap therapies for chronic diseases, are prominent factors driving the market's growth. Additionally, the surging penetration for the detection of virus removal or inactivation during the early stages of development and rising preference for outsourcing of viral clearances among leading pharma and biotechnology companies, are further anticipated to boost global market growth.

For instance, in June 2023, Texcell, announced about the opening of its newest testing facility in North America that shows company's commitment towards advancing the viral safety of biotherapeutics and medical devices. The new facility is specially designed to support simultaneous viral clearance and biosafety studies.

There are several methods being used for testing of harmful viruses in biologics. There is an increasing proliferation for the advent of next-generation sequencing which holds great promise in accurate and fast detection of known and unknown contaminating viruses. It allows sensitive and specific testing of wide range of viral contaminants, creating a growth potential for the market. For instance, in July 2023, Integrated DNA Technologies, unveiled its new next-generation sequencing solution called "xGen Respiratory Virus Amplicon Panel".

Furthermore, there has been an increase in the awareness about viral safety and its significance in the healthcare industry, which has been underlined by several types of viral illnesses like Human Immunodeficiency Virus, hepatitis, and Zika virus. Also, the need for gene treatments and personalized medicine that allows for the development of targeted antiviral treatments and enhanced immune response, which in turn, generating huge growth potential for the market.

Viral Clearance Market Report Highlights

Viral removal method segment accounted for the noteworthy share, due to its beneficial properties and rising emergence of new virus threats globally

Vaccines segment held the largest share, that is driven by increasing demand and need for various types of vaccines to boost immunization of patient

CROs segment will grow at substantial growth rate, on account of growing prevalence for outsourcing of early-phase development and testing services

Asia Pacific will grow fastest, due to presence of huge untapped market and rising disposable income

North America dominated the global market, on account of region's greater awareness about the importance of viral clearance

The key market players include Charles River Laboratories, Merck KgaA, Syngene International Limited, WuXi Biologics, Clean Cells, and Allure Medical Group

Polaris Market Research has segmented the viral clearance market report based on method, application, end user, and region:

Viral Clearance, Method Outlook (Revenue - USD Million, 2019 - 2032)

  • Viral Removal Method
  • Viral Inactivation Method
  • Viral Detection Method

Viral Clearance, Application Outlook (Revenue - USD Million, 2019 - 2032)

  • Blood and Blood Products
  • Recombinant Proteins
  • Cellular & Gene
  • Therapy Products
  • Vaccines
  • Others

Viral Clearance, End User Outlook (Revenue - USD Million, 2019 - 2032)

  • Pharmaceutical and Biotech Industry
  • Academic Research Institutes
  • CROs
  • Others

Viral Clearance, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Viral Clearance Market Insights

  • 4.1. Viral Clearance Market - End User Snapshot
  • 4.2. Viral Clearance Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing demand for biologics and vaccines and rise in R&D expenditure are major factors propelling market growth
      • 4.2.1.2. Rising Incidence of Viral Infections
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Complexity of Viral Clearance Techniques
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Viral Clearance Market End User Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Viral Clearance Market, by Method

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Viral Clearance Market, by Method, 2019-2032 (USD Million)
  • 5.3. Viral Removal Method
    • 5.3.1. Global Viral Clearance Market, by Viral Removal Method, by Region, 2019-2032 (USD Million)
  • 5.4. Viral Inactivation Method
    • 5.4.1. Global Viral Clearance Market, by Viral Inactivation Method, by Region, 2019-2032 (USD Million)
  • 5.5. Viral Detection Method
    • 5.5.1. Global Viral Clearance Market, by Viral Detection Method, by Region, 2019-2032 (USD Million)

6. Global Viral Clearance Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Viral Clearance Market, by Application, 2019-2032 (USD Million)
  • 6.3. Blood and Blood Products
    • 6.3.1. Global Viral Clearance Market, by Blood and Blood Products, by Region, 2019-2032 (USD Million)
  • 6.4. Recombinant Proteins
    • 6.4.1. Global Viral Clearance Market, by Recombinant Proteins, by Region, 2019-2032 (USD Million)
  • 6.5. Cellular & Gene Therapy Products
    • 6.5.1. Global Viral Clearance Market, by Cellular & Gene Therapy Products, by Region, 2019-2032 (USD Million)
  • 6.6. Vaccines
    • 6.6.1. Global Viral Clearance Market, by Vaccines, by Region, 2019-2032 (USD Million)
  • 6.7. Others
    • 6.7.1. Global Viral Clearance Market, by Others, by Region, 2019-2032 (USD Million)

7. Global Viral Clearance Market, by End User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Viral Clearance Market, by End User, 2019-2032 (USD Million)
  • 7.3. Pharmaceutical and Biotech Industry
    • 7.3.1. Global Viral Clearance Market, by Pharmaceutical and Biotech Industry, By Region, 2019-2032 (USD Million)
  • 7.4. Academic Research Institutes
    • 7.4.1. Global Viral Clearance Market, by Academic Research Institutes, By Region, 2019-2032 (USD Million)
  • 7.5. CROs
    • 7.5.1. Global Viral Clearance Market, by CROs, By Region, 2019-2032 (USD Million)
  • 7.6. Others
    • 7.6.1. Global Viral Clearance Market, by Others, By Region, 2019-2032 (USD Million)

8. Global Viral Clearance Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Viral Clearance Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Viral Clearance Market - North America
    • 8.3.1. North America: Viral Clearance Market, by Method, 2019-2032 (USD Million)
    • 8.3.2. North America: Viral Clearance Market, by End User, 2019-2032 (USD Million)
    • 8.3.3. North America: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.3.4. Viral Clearance Market - U.S.
      • 8.3.4.1. U.S.: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.3.5. Viral Clearance Market - Canada
      • 8.3.5.1. Canada: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Viral Clearance Market, by Application, 2019-2032 (USD Million)
  • 8.4. Viral Clearance Market - Europe
    • 8.4.1. Europe: Viral Clearance Market, by Method, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
    • 8.4.3. Europe: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.4.4. Viral Clearance Market - UK
      • 8.4.4.1. UK: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.4.5. Viral Clearance Market - France
      • 8.4.5.1. France: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.4.5.3. France: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.4.6. Viral Clearance Market - Germany
      • 8.4.6.1. Germany: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.4.7. Viral Clearance Market - Italy
      • 8.4.7.1. Italy: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.4.8. Viral Clearance Market - Spain
      • 8.4.8.1. Spain: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.4.9. Viral Clearance Market - Netherlands
      • 8.4.9.1. Netherlands: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.4.10. Viral Clearance Market - Russia
      • 8.4.10.1. Russia: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Viral Clearance Market, by Application, 2019-2032 (USD Million)
  • 8.5. Viral Clearance Market - Asia Pacific
    • 8.5.1. Asia Pacific: Viral Clearance Market, by Method, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.5.4. Viral Clearance Market - China
      • 8.5.4.1. China: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.5.4.3. China: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.5.5. Viral Clearance Market - India
      • 8.5.5.1. India: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.5.5.3. India: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.5.6. Viral Clearance Market - Malaysia
      • 8.5.6.1. Malaysia: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.5.7. Viral Clearance Market - Japan
      • 8.5.7.1. Japan: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.5.8. Viral Clearance Market - Indonesia
      • 8.5.8.1. Indonesia: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.5.9. Viral Clearance Market - South Korea
      • 8.5.9.1. South Korea: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Viral Clearance Market, by Application, 2019-2032 (USD Million)
  • 8.6. Viral Clearance Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Viral Clearance Market, by Method, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.6.4. Viral Clearance Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.6.5. Viral Clearance Market - UAE
      • 8.6.5.1. UAE: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.6.6. Viral Clearance Market - Israel
      • 8.6.6.1. Israel: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.6.7. Viral Clearance Market - South Africa
      • 8.6.7.1. South Africa: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Viral Clearance Market, by Application, 2019-2032 (USD Million)
  • 8.7. Viral Clearance Market - Latin America
    • 8.7.1. Latin America: Viral Clearance Market, by Method, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.7.4. Viral Clearance Market - Mexico
      • 8.7.4.1. Mexico: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.7.5. Viral Clearance Market - Brazil
      • 8.7.5.1. Brazil: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Viral Clearance Market, by Application, 2019-2032 (USD Million)
    • 8.7.6. Viral Clearance Market - Argentina
      • 8.7.6.1. Argentina: Viral Clearance Market, by Method, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Viral Clearance Market, by End User, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Viral Clearance Market, by Application, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Allure Medical Group
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Charles River Laboratories
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Clean Cells
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Creative Biogene
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Eurofins Scientific SE
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Kedrion
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Labor Dr. Merk & Kollegen GmbH
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Merck KGaA
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Microbiologics
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Sartorius AG
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Syngene International Limited
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Texcell
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. ViruSure GmbH
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Wuxi Biologics
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦